Dabitao D, Bishai WR. Sex and Gender Differences in Tuberculosis Pathogenesis and Treatment Outcomes. Curr Top Microbiol Immunol. 2023;441:139-183. doi: 10.1007/978-3-031-35139-6_6. PMID: 37695428.
Archives: Publications
Publications
Functional Whole Genome Screen of Nutrient-Starved Mycobacterium tuberculosis Identifies Genes Involved in Rifampin Tolerance
Matern WM, Harris HT, Danchik C, et al. Functional Whole Genome Screen of Nutrient-Starved Mycobacterium tuberculosis Identifies Genes Involved in Rifampin Tolerance. Microorganisms. 2023;11(9):2269. Published 2023 Sep 9. doi:10.3390/microorganisms11092269
Glycated Hemoglobin Trajectories and Their Association With Treatment Outcomes Among Patients With Pulmonary TB in India: A Prospective Cohort Study
Pardeshi G, Mave V, Gaikwad S, Kadam D, Barthwal M, Gupte N, Atre S, Deshmukh S, Golub JE, Gupte A. Glycated Hemoglobin Trajectories and Their Association With Treatment Outcomes Among Patients With Pulmonary TB in India: A Prospective Cohort Study. Chest. 2024 Feb;165(2):278-287. doi: 10.1016/j.chest.2023.08.026. Epub 2023 Sep 4. PMID: 37673207; PMCID: PMC10851276.
Perceived stigma among people with TB and household contacts
Machavariani E, Nonyane BAS, Lebina L, Mmolawa L, West NS, Dowdy DW, Martinson N, Ahmad B, Hanrahan CF. Perceived stigma among people with TB and household contacts. Int J Tuberc Lung Dis. 2023 Sep 1;27(9):675-681. doi: 10.5588/ijtld.22.0670. PMID: 37608483; PMCID: PMC10443789.
Determining cost and placement decisions for moderate complexity NAATs for tuberculosis drug susceptibility testing
Malhotra A, Thompson R, De Vos M, David A, Schumacher S, Sohn H. Determining cost and placement decisions for moderate complexity NAATs for tuberculosis drug susceptibility testing. PLoS One. 2023 Aug 24;18(8):e0290496. doi: 10.1371/journal.pone.0290496. PMID: 37616318; PMCID: PMC10449112.
Timing of maternal isoniazid preventive therapy on tuberculosis infection among infants exposed to HIV in low-income and middle-income settings: a secondary analysis of the TB APPRISE trial
Gupta A, Singh P, Aaron L, Montepiedra G, Chipato T, Stranix-Chibanda L, Chanaiwa V, Vhembo T, Mutambanengwe M, Masheto G, Raesi M, Bradford S, Golner A, Costello D, Kulkarni V, Shayo A, Kabugho E, Jean-Phillippe P, Chakhtoura N, Sterling TR, Theron G, Weinberg A; IMPAACT P1078 TB APPRISE Study Team. Timing of maternal isoniazid preventive therapy on tuberculosis infection among infants exposed to HIV in low-income and middle-income settings: a secondary analysis of the TB APPRISE trial. Lancet Child Adolesc Health. 2023 Oct;7(10):708-717. doi: 10.1016/S2352-4642(23)00174-8. Epub 2023 Aug 24. PMID: 37634517.
Modeling the impact of universal tuberculosis molecular testing and timing of tuberculosis preventive treatment during antiretroviral therapy initiation in South Africa
Balasubramanian R, Shearer K, Mudzengi D, Hippner P, Golub JE, Chihota V, Hoffmann CJ, Kendall EA. Modeling the impact of universal tuberculosis molecular testing and timing of tuberculosis preventive treatment during antiretroviral therapy initiation in South Africa. AIDS. 2023 Dec 1;37(15):2371-2379. doi: 10.1097/QAD.0000000000003707. Epub 2023 Aug 30. PMID: 37650763; PMCID: PMC10782927.
Undiagnosed Pulmonary Tuberculosis (TB) and Coronavirus Disease 2019 (COVID-19) in Adults Dying at Home in a High-TB-Burden Setting, Before and During Pandemic COVID-19: An Autopsy Study
Sabet N, Omar T, Milovanovic M, Magajane T, Mosala M, Moloantoa T, Kato-Kalule N, Semedo LV, Swanepoel F, Wallis C, Abraham P, Lebina L, Variava E, Martinson N. Undiagnosed Pulmonary Tuberculosis (TB) and Coronavirus Disease 2019 (COVID-19) in Adults Dying at Home in a High-TB-Burden Setting, Before and During Pandemic COVID-19: An Autopsy Study. Clin Infect Dis. 2023 Aug 14;77(3):453-459. doi: 10.1093/cid/ciad212. PMID: 37041678.
Comparative immune responses to Mycobacterium tuberculosis in people with latent infection or sterilizing protection
Jalbert E, Liu C, Mave V, Lang N, Kagal A, Valvi C, Paradkar M, Gupte N, Lokhande R, Bharadwaj R, Kulkarni V, Gupta A, Weinberg A.
Translational predictions of phase 2a first-in-patient efficacy studies for antituberculosis drugs
Ernest JP, Ni Goh JJ, Strydom N, Wang Q, van Wijk RC, Zhang N, Deitchman A, Nuermberger E, Savic RM. Translational predictions of phase 2a first-in-patient efficacy studies for antituberculosis drugs. bioRxiv [Preprint]. 2023 Jan 20:2023.01.18.524608. doi: 10.1101/2023.01.18.524608. Update in: Eur Respir J. 2023 Jun 15;: PMID: 36711493; PMCID: PMC9882354.